
|Podcasts|April 21, 2021
Dr. Robert J. Hamilton on statin use in men starting ADT for prostate cancer
Author(s)Urology Times staff
Hamilton discusses findings from a recent study published in European Urology.
Advertisement
“The patients who use statins had longer overall survival, longer prostate cancer-specific survival, and a trend towards longer time before they became castration resistant,” Robert J. Hamilton, MD, MPH, says in this podcast. Hamilton is an associate professor of urology at the University of Toronto.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves capivasertib plus abiraterone and prednisone for PTEN-deficient mHSPC
2
Toni Choueiri, MD, reacts to FDA approval of adjuvant belzutifan with pembrolizumab for ccRCC
3
Dean Elterman, MD, highlights efficacy and safety data on the Zenflow Prostatic Spring
4
FDA approves adjuvant belzutifan with pembrolizumab for ccRCC
5











